JP2008504248A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008504248A5 JP2008504248A5 JP2007517215A JP2007517215A JP2008504248A5 JP 2008504248 A5 JP2008504248 A5 JP 2008504248A5 JP 2007517215 A JP2007517215 A JP 2007517215A JP 2007517215 A JP2007517215 A JP 2007517215A JP 2008504248 A5 JP2008504248 A5 JP 2008504248A5
- Authority
- JP
- Japan
- Prior art keywords
- angiopoietin
- tie
- polypeptide
- modulator
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims 15
- 102000005450 TIE receptors Human genes 0.000 claims 12
- 108010006830 TIE receptors Proteins 0.000 claims 12
- 108010009906 Angiopoietins Proteins 0.000 claims 11
- 102000009840 Angiopoietins Human genes 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 238000000034 method Methods 0.000 claims 8
- 150000001413 amino acids Chemical group 0.000 claims 7
- 102100033402 Angiopoietin-4 Human genes 0.000 claims 6
- 108010069801 angiopoietin 4 Proteins 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 230000035558 fertility Effects 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 108010090089 TIE-1 Receptor Proteins 0.000 claims 4
- 108010090091 TIE-2 Receptor Proteins 0.000 claims 4
- 230000013020 embryo development Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 108010048036 Angiopoietin-2 Proteins 0.000 claims 3
- 102000009075 Angiopoietin-2 Human genes 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 108010048154 Angiopoietin-1 Proteins 0.000 claims 2
- 102000009088 Angiopoietin-1 Human genes 0.000 claims 2
- 101100481404 Danio rerio tie1 gene Proteins 0.000 claims 2
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 2
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 2
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 claims 2
- 102000050000 TIE-1 Receptor Human genes 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 claims 1
- 102000012753 TIE-2 Receptor Human genes 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000004081 cilia Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 102000044072 human ANGPT1 Human genes 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 230000016087 ovulation Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001766 physiological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58285804P | 2004-06-25 | 2004-06-25 | |
| PCT/EP2005/006906 WO2006002854A2 (en) | 2004-06-25 | 2005-06-27 | Tie receptor and tie ligand materials and methods for modulating female fertility |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008504248A JP2008504248A (ja) | 2008-02-14 |
| JP2008504248A5 true JP2008504248A5 (enExample) | 2008-07-24 |
Family
ID=34972915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007517215A Withdrawn JP2008504248A (ja) | 2004-06-25 | 2005-06-27 | Ｔｉｅ受容体およびＴｉｅリガンド物質および雌受胎能を制御する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070280947A1 (enExample) |
| EP (1) | EP1778264A2 (enExample) |
| JP (1) | JP2008504248A (enExample) |
| AU (1) | AU2005259537A1 (enExample) |
| CA (1) | CA2571752A1 (enExample) |
| WO (1) | WO2006002854A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| AU2001259432B2 (en) * | 2000-05-03 | 2005-04-21 | Amgen Inc. | Modified peptides, comprising an FC domain, as therapeutic agents |
| WO2008109369A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof |
| AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| CN106432506A (zh) | 2011-05-24 | 2017-02-22 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
| GB201223053D0 (en) * | 2012-12-20 | 2013-02-06 | Medical Res Council | Receptor |
| EP3424530A1 (en) | 2013-03-15 | 2019-01-09 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643755A (en) * | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
| WO1998018914A1 (en) * | 1996-10-31 | 1998-05-07 | Duke University | Soluble tie2 receptor |
| ES2262518T5 (es) * | 1999-06-07 | 2009-05-08 | Immunex Corporation | Antagonistas de tek. |
| AU2001287268A1 (en) * | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Method of identifying inhibitors of tie-2 |
| US7348001B2 (en) * | 2003-08-12 | 2008-03-25 | Dyax Corp. | Tie1-binding ligands |
-
2005
- 2005-06-27 EP EP05757015A patent/EP1778264A2/en not_active Withdrawn
- 2005-06-27 WO PCT/EP2005/006906 patent/WO2006002854A2/en not_active Ceased
- 2005-06-27 CA CA002571752A patent/CA2571752A1/en not_active Abandoned
- 2005-06-27 US US11/630,531 patent/US20070280947A1/en not_active Abandoned
- 2005-06-27 AU AU2005259537A patent/AU2005259537A1/en not_active Abandoned
- 2005-06-27 JP JP2007517215A patent/JP2008504248A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103124788B (zh) | 双特异性融合蛋白 | |
| US11673949B2 (en) | Method of modulating the adrenomedullin (ADM) activity of a patient by administering to the patient an anti-ADM antibody or fragment thereof that specifically binds to mature human ADM | |
| US10227405B2 (en) | Methods of modulating the activity of adrenomedullin in a subject in need of regulation of fluid balance by administering an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment | |
| OA12890A (en) | Methods of diagnosing and treating pre-eclampsia or eclampsia. | |
| CN105358175B (zh) | 用于治疗硬皮病的抗ccl2和抗loxl2组合疗法 | |
| KR20130133247A (ko) | Ｉｌ-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| KR20190113995A (ko) | 요법에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드 | |
| CN105524176A (zh) | 双特异性融合蛋白 | |
| KR20250004742A (ko) | 자궁내막증 및 다른 양성 부인과 신생물의 치료를 위한 제제 | |
| DK2984108T3 (en) | Anti-s100a7 antibodies for the treatment and diagnosis of cancer | |
| JP2008504248A5 (enExample) | ||
| WO2022026643A1 (en) | Interleukin-22 fusion proteins, and their pharmaceutical compositions and therapeutic applications | |
| US11117976B2 (en) | Compositions and methods for regulating erythropoiesis | |
| JP2014515743A (ja) | Ｔｇｆ−アルファおよびエピレグリンに結合する抗体 | |
| BR112019023141A2 (pt) | métodos de tratamento seletivo da asma usando antagonistas de il-17 | |
| TW202334241A (zh) | 治療硬皮病之方法 | |
| US20210009672A1 (en) | Methods of treating or preventing liver fibrosis with inhibition of activins a & b | |
| HK40082763A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition | |
| WO2025086801A1 (zh) | 一种全人源tsh受体阻断性单克隆抗体及其制备和应用 | |
| CN118344475A (zh) | 一种抗aibp单克隆抗体及其应用 | |
| US20180008723A1 (en) | Multimeric compounds of a kringle domain from the hepatocyte growth factor / scatter factor (hgf/sf) | |
| NZ624875B2 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy | |
| NZ624869B2 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition | |
| NZ624876B2 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
| HK1190410B (en) | Antibodies that bind tgf-alpha and epiregulin |